Adagio Medical Holdings, Inc. (ADGM)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Olav B. Bergheim | President, CEO, Secretary & Executive Director | 88.74k | -- | 1950 |
Mr. John T. Dahldorf | Chief Financial Officer | 405.34k | -- | 1957 |
Mr. Hakon Bergheim | Chief Operating Officer | 398.12k | -- | -- |
Dr. Alex Babkin Ph.D. | Chief Technical Officer | -- | -- | -- |
Mr. Nabil Jubran | Chief Compliance Officer | -- | -- | -- |
Ilya Grigorov | Vice President of Global Marketing & Product Management | -- | -- | -- |
Tim Glynn | Vice President of Global Sales | -- | -- | -- |
Adagio Medical Holdings, Inc.
- Sector:?
- Healthcare
- Industry:? Medical Devices
- Full Time Employees:?
- 87
Description
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company was founded in 2011 and is headquartered in Laguna Hills, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
July 23, 2024 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
July 11, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
July 2, 2024 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions